Loobie wrote:Jane,
I was thinking the same thing. However, their stock is low now and I would imagine Opexa will be known as a subsidiary of Biogen or Teva before it goes up!
Until recently, the thought of this really annoyed me--after all, the Opexa people have done the dog-work making this wonderful stuff so possible.
But I have to keep the big picture well in mind: they're going to need those big bucks when it comes time to segue into Phase III. One of my husband's stock reports claimed they've got an outlay of a million bucks a month for this--and that's just the follow-up for the first round of guinea pigs and those of us in Phase II.
So I'm going to have to endure having my sense of fair play outraged and just deal with it. After all, it'll mean treatment for so very many people.
Let's just hope it never turns into the mess Tysabri did--all that price-gouging when it was re-introduced. To think of patients not getting a workable therapy because of cost considerations--that's obscene.
So if someone can allay my fears about Tovaxin turning into a cash cow for a Big Shot pharma and not getting where it needs to go, I'll be okay.
That and making sure the doc who got this ball rolling in the first place gets the Nobel Prize for Medicine. At the very least!
